Blood-Derived Plasma Protein Biomarkers for Alzheimer’s Disease in Han Chinese
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
It is well known that Alzheimer’s disease (AD) is one of the most common progressive neurodegenerative diseases; it begins gradually, and therefore, no effective medicine is administered in the beginning. Thus, the early diagnosis and prevention of AD is crucial. The present study focused on comparing the plasma protein changes between patients with AD and their healthy counterparts, aiming to explore a specific protein panel as a potential biomarker for AD patients in Han Chinese. Hence, we recruited and collected plasma samples from 98 AD patients and 101 elderly healthy controls from Wuxi and Shanghai Mental Health Centers. Using Luminex assay, we investigated the expression levels of fifty plasma proteins in these samples. Thirty-two out of fifty proteins were found to be significantly different between AD patients and healthy controls (P < 0.05). Furthermore, an eight-protein panel that included brain-derived neurotrophic factor (BDNF), angiotensinogen (AGT), insulin-like growth factor binding protein 2 (IGFBP-2), osteopontin (OPN), cathepsin D, serum amyloid P component (SAP), complement C4, and prealbumin (transthyretin, TTR) showed the highest determinative score for AD and healthy controls (all P = 0.00). In conclusion, these findings suggest that a combination of eight plasma proteins can serve as a promising diagnostic biomarker for AD with high sensitivity and specificity in Han Chinese populations; the eight plasma proteins were proven important for AD diagnosis by further cross-validation studies within the AD cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Recent genome-wide association studies (GWAS) have identified the association of complement receptor 1 with AD (Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010; Naj et al., 2011).”
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Hypertension and Cerebrovascular Dysfunction
Iadecola, C., & Davisson, R. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.010 · Cited by 557
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., Soekadar, S., Richartz, E., Koehler, N., Bartels, M., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.014 · Cited by 272
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease
Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M. G., Arighi, A., Fumagalli, G., & Scarpini, E. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140756 · Cited by 222
Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Wu, Y.-T., Ali, G.-C., Guerchet, M., Prina, A. M., Chan, K. Y., Prince, M., & Brayne, C. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy007 · Cited by 157
Self-citationDeaths from Alzheimer’s Disease — United States, 1999–2014
Taylor, C. A., Greenlund, S. F., McGuire, L. C., Lu, H., & Croft, J. B. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6620a1 · Cited by 144
Wilson, M. R., Yerbury, J. J., & Poon, S. (2007) · Molecular BioSystems · doi:10.1039/b712728f · Cited by 142
Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135
Mold, M., Shrive, A. K., & Exley, C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120076 · Cited by 26 · cited 1×
“…been considered to be interesting and potentially significant in AD disease pathology in previous studies (Phillips et al., 1991; Iadecola and Davisson, 2008; Carecchio and Comi, 2011; Daborg et al., 2012; Mold et al., 2012; Tian et al., 2014; Willette et al., 2015; Buxbaum and Johansson, 2017).”
Result
Cited by
Zimetti, F., Adorni, M. P., Marsillach, J., Marchi, C., Trentini, A., Valacchi, G., & Cervellati, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6695796 · Cited by 49
“More specifically, we found two studies reporting higher levels of this enzyme in the plasma of AD patients compared with cognitively normal subjects [39, 40] and two studies with no differences detected [41, 42].”
ResultPhosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
Qin, W., Li, F., Jia, L., Wang, Q., Li, Y., Wei, Y., Li, Y., Jin, H., & Jia, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.900773 · Cited by 23
Rehman, H., Initiative, F. T. A. D. N., Ang, T. F. A., Tao, Q., Espenilla, A. L., Au, R., Farrer, L. A., Zhang, X., & Qiu, W. Q. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230837 · Cited by 7
Metadata
- Authors
- Cheng, Z., Yin, J., Yuan, H., Jin, C., Zhang, F., Wang, Z., Liu, X., Wu, Y., Wang, T., & Xiao, S.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-12-17
- Volume
- 10
- Pages
- 414-414
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2905563819
- Cited by
- 37
- References
- 18
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.